Patrick Hwu: AntiPD1 in combination with antilag3 and ctla4 in head and neck cancers
Patrick Hwu, President and CEO of Moffitt Cancer Center, shared an article by Housaiyin Li, et al. on LinkedIn:
“Increasing evidence suggests giving immunotherapy before surgery (neoadjuvant) is better than after surgery (adjuvant).
In a recent report investigators compared neoadjuvant single agent anti-PD1 to combinations with anti-PD1 and either anti-LAG3 or anti-CTLA4 antibodies in patients with head and neck cancers.
Both combinations were more effective than single agent but the combination with anti-CTLA4 had more toxicity. In addition the combinations activated different T cell populations. The combination with anti-CTLA4 activated effector CD8 T cells in the tumor whereby the combination with anti-LAG3 was capable of reprogramming some exhausted CD8 T cell populations.
Understanding the mechanisms of these immunotherapy combinations will enhance our ability to personalize and optimize immunotherapy to improve outcomes.
Here’s a link to the full article.”
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies.
Authors: Housaiyin Li, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023